3 completed, 1 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow AL101: new trials by email Literature Review of AL101 trials Research Report on AL101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer AL101, Therapeutic Conventional Surgery - Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 13 | 2021-09-30 | 2026-06-24 |
| A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer AL101 - Triple Negative Breast Cancer | Phase 2 | Terminated | Ayala Pharmaceuticals, Inc, | 18 | 2020-08-14 | 2024-02-12 |
| A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 AL101, Placebo - Healthy | Phase 1 | Completed | Alector Inc. | 88 | 2019-12-14 | 2022-08-10 |
| A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations AL101 - Adenoid Cystic Carcinoma | Phase 2 | Completed | Ayala Pharmaceuticals, Inc, | 87 | 2018-12-14 | 2024-01-31 |
Carcinoma, Adenoid Cystic (2) · Triple Negative Breast Neoplasms (1)
Ayala Pharmaceuticals, Inc, (2) · Alector Inc. (1) · M.D. Anderson Cancer Center (1)
United States (4) · Israel (2) · United Kingdom (2) · Belgium (1) · Canada (1) · France (1) · Netherlands (1) · Spain (1)
Andres Gutierrez, MD, PhD (1) · Jorge Kusnir (1) · Maria Bermudez (1) · Renata Ferrarotto (1)